Xavier Fradera

This inventor holds 24 USPTO granted patents and 4 published patent applications and 16 EPO patents, primarily in IDO Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xavier Fradera. Retrieved from https://idiyas.com/inventor/xavier-fradera

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 24 (Patent Applications = 4)

% Patents Active = 87.5

EPO Patents = 16 (Patent Applications = 27)

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Needham, MA (US) (2021)
Boston, MA (US) (2021 - 2022)
Brookline, MA (US) (2020 - 2024)

Company Filing History:

19 out of 2,405

Merck Sharp + Dohme Corp.

patents

5 out of 70

Merck Sharp & Dohme LLC

patents

Years Active: 2020-2026

Loading Chart...

Areas of Expertise:

IDO Inhibitors

HPK1 Inhibitors

RIPK1 Inhibitors

Indoleamine

Pyrimidine Compounds

Quinazoline Compounds

Phenyl Compounds

Pyrazole Compounds

Tetrahydroquinoline

Piperazine Amides

Cyclobutyl Compounds

Purine Inhibitors

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753190 - Spirotricycle RIPK1 inhibitors and methods of uses thereof (2026-10-06),

2. 12753163 - Diaminopyrimidine carboxamide inhibitors of HPK1 (2026-10-06),

3. 12735431 - 7-phenyl substituted 2-aminoquinazoline inhibitors of HPK1 (2026-09-15),

4. 12643904 - RIPK1 inhibitors and methods of use (2026-06-02),

5. 12576087 - Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2026-03-17),

6. 12275729 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-14),

7. 12264134 - Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-01),

8. 12180226 - Spirotricycle RIPK1 inhibitors and methods of uses thereof (2024-12-31),

9. 12157727 - Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2024-12-03),

10. 12152019 - Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-11-26),

11. 12091405 - Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-09-17),

12. 11992489 - Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors (2024-05-28),

13. 11498904 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-11-15),

14. 11478461 - [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-10-25),

15. 11319283 - Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),

Certainly! Here is the article about inventor Xavier Fradera:

Title: Innovator Spotlight: Xavier Fradera - Pioneering Researcher in Pharmaceutical Innovation

Introduction:

Xavier Fradera, a distinguished inventor based in Boston, MA, is making waves in the field of pharmaceuticals with his groundbreaking research and numerous patents. With a total of 13 patents to his name, Fradera is at the forefront of developing cutting-edge medical treatments.

Latest Patents:

Fradera's latest patents include Substituted Tetrahydroquinoline Compounds as Indoleamine 2,3-Dioxygenase Inhibitors. These compounds serve as inhibitors of an IDO enzyme, showing promise in the treatment and prevention of IDO-associated diseases and disorders. Additionally, his work on Substituted Biaryl Compounds as IDO Inhibitors highlights his commitment to advancing medical science.

Career Highlights:

Currently affiliated with Merck Sharp & Dohme Corporation, Fradera is instrumental in driving innovation within the pharmaceutical industry. His expertise and dedication have led to the development of novel therapeutic approaches that have the potential to transform patient care.

Collaborations:

Fradera's collaborations with esteemed coworkers such as Yongxin Han and Abdelghani Achab have further enriched his research endeavors. Together, they strive to push the boundaries of pharmaceutical innovation and create solutions that address unmet medical needs.

Conclusion:

Xavier Fradera's prolific career as an inventor underscores his commitment to pioneering scientific advancements in the pharmaceutical sector. His patents and collaborations reflect a deep-seated passion for improving healthcare outcomes and shaping the future of medicine. Fradera's contributions continue to inspire and drive progress within the industry, making him a true trailblazer in the field of pharmaceutical innovation.

Profile summary based on public USPTO records.